@article{ATM14076,
author = {Anant Ramaswamy and Munita Bal and Rohit Swami and Omshree Shetty and Subhadeep Bose and Trupti Pai and Mamta Gurav and Sudeep Gupta and Vikas Ostwal},
title = {Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib},
journal = {Annals of Translational Medicine},
volume = {5},
number = {6},
year = {2017},
keywords = {},
abstract = {Background: The exon 11 KIT mutant gastrointestinal stromal tumors (GIST) is a heterogeneous cohort with variable biological behavior based on different mutational subtypes.
Methods: Patients with histologically prove n GIST with KIT exon 11 mutations were selected from a prospectively maintained database, and evaluated for clinical characteristics and event free survival (EFS). Patients were divided into mutations upstream to codon 557 (G1), mutations involving codon 557-558 (G2) and mutation downstream to codon 558 (G3).
Results: A total of 90 patients satisfied the inclusion criteria for study. Substitutions, indels and duplications were seen in 23 patients. Deletions were seen in 67 patients, of which 44 patients had large deletions (>6 base pairs), while 23 has small deletions (},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/14076}
}